Antibody-Drug Conjugates: Looking Ahead to an Emerging Class of Biotherapeutic - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Antibody-Drug Conjugates: Looking Ahead to an Emerging Class of Biotherapeutic
Creating a successful antibody-drug conjugate requires careful selection of the drug, antibody, and linker.


Pharmaceutical Technology
Volume 36, Issue 1, pp. 42-47

Looking ahead

The future of ADCs in the biopharmaceutical market will ultimately depend on their clinical success. Companies and researchers are seeking to meet that challenge by optimizing the selection of all the components in the ADC—the antibody, linker, and cytotoxin—and successfully combining manufacturing techniques for both high- potency APIs and biologics. ADCs are sometimes described as armed antibodies, and their cytotoxic components as warheads. Whether ADCs will prove to be an effective weapon against cancer or other diseases has yet to be seen as more are tested in the clinic.

References

1. FDA, "Label for Adcetris, BLA 125338," FDA Approved Drug Products: Drugs@FDA, accessed Dec. 20, 2011.

2. V.S. Goldmacher and Y.V. Kovtun, Ther. Deliv. 2 (3), 397–416 (2011).

3. F. Dosio, P. Brusa and L. Cattel, Toxins 3, 848–883 (2011).

4. H.A. Burris, Expert Opin. Biol. Ther. 11 (6), 807–819 (2011).

5. A. Beck et al., Discov. Med. 10 (53), 329–359 (2010).

6. S.V. Govindan and DM Goldenberg, Scientific World Journal 10, 2070–2089 (2010).

7. Junutula et al., Nat. Biotechnol. 26 (8), 925-932 (2008).

8. Junutula et al., Clin. Canc. Res. 16, 4769–4778 (2010).

9. A. Ritter Pharm. Tech. 35 (6), 36–39 (2011).

10. Zawada et al., Biotech. Bioeng. 108 (7), 1570–1578 (2011).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
27%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
8%
All of the above.
41%
No government involvement in patient treatment or drug development.
11%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Source: Pharmaceutical Technology,
Click here